NCT06283927 2024-02-28
RECSUR
Erasmus Medical Center
Recruiting
Clinical Trials
13 trialsNCT02843230 2022-04-08
Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI
Massachusetts General Hospital
Completed
NCT00943462 2020-07-23
Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM
Centre hospitalier de l'Université de Montréal (CHUM)
Withdrawn
NCT03567135 2020-03-03
Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
Fuzhou General Hospital
Unknown
NCT03631823 2018-08-15
Gut Microbiota and Glioblastoma Multiforme Prognosis
Huashan Hospital
Unknown
NCT00471653 2018-07-09
Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Terminated
NCT02329795 2017-10-12
IDEPREG
Rigshospitalet, Denmark
Terminated
NCT03225963 2017-07-24
Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.
Taichung Veterans General Hospital
Unknown
NCT00705198 2016-11-15
Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
Merck Sharp & Dohme LLC
Completed
NCT01345370 2016-01-29
ECOM
Center Eugene Marquis
Completed
NCT00704808 2015-09-09
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
Merck Sharp & Dohme LLC
Completed
NCT00725010 2015-09-09
Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)
Merck Sharp & Dohme LLC
Completed
NCT00723827 2015-01-30
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Merck Sharp & Dohme LLC
Completed